These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23442295)

  • 1. Pharmacovigilance on the turn? Adverse reactions methods in 2012.
    Herxheimer A
    Int J Risk Saf Med; 2013 Jan; 25(1):29-31. PubMed ID: 23442295
    [No Abstract]   [Full Text] [Related]  

  • 2. [New methods for studying drug associated risk: experience of the Toulouse Regional Pharmacovigilance Center].
    Montastruc JL; Bagheri H; Lacroix I; Olivier P; Durrieu G; Damase-Michel C; Lapeyre-Mestre M
    Bull Acad Natl Med; 2005 Mar; 189(3):493-502; discussion 502-5. PubMed ID: 16149213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug vigilance: opinion survey among residents of a university hospital].
    Graille V; Lapeyre-Mestre M; Montastruc JL
    Therapie; 1994; 49(5):451-4. PubMed ID: 7855763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving pharmacovigilance. Use of routinely collected data.
    Molokhia M; Curcin V; Majeed A
    BMJ; 2010 May; 340():c2403. PubMed ID: 20442236
    [No Abstract]   [Full Text] [Related]  

  • 5. Serious adverse drug reactions in older adults notified to pharmacovigilance.
    Charfi R; El Aïdli S; Zaïem A; Kastalli S; Sraïri S; Daghfous R; Lakhal M
    Therapie; 2012; 67(5):465-70. PubMed ID: 23241256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse drug reactions in older adults: a retrospective study from pharmacovigilance.
    Charfi R; El Aïdli S; Zaïem A; Kastalli S; Sraïri S; Daghfous R; Lakhal M
    Therapie; 2012; 67(5):471-6. PubMed ID: 23241257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European pharmacovigilance: an overview of pharmacovigilance inspections.
    Koster MC; van den Oetelaar AH
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):711-3. PubMed ID: 16142691
    [No Abstract]   [Full Text] [Related]  

  • 8. Detecting adverse drug reactions.
    Rosenbloom D; Wynne C
    CMAJ; 1999 Aug; 161(3):247-8. PubMed ID: 10463044
    [No Abstract]   [Full Text] [Related]  

  • 9. Potential utility of data-mining algorithms for early detection of potentially fatal/disabling adverse drug reactions: a retrospective evaluation.
    Hauben M; Reich L
    J Clin Pharmacol; 2005 Apr; 45(4):378-84. PubMed ID: 15778418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacovigilance of medicinal products in Poland--new guidelines].
    Jabłecka A; Korzeniowska K; Balcer-Dymel N
    Przegl Lek; 2012; 69(10):1127-8. PubMed ID: 23421106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Underreporting adverse drug reactions--limitations of the Dutch Hospital Data database].
    Dijkers FW
    Ned Tijdschr Geneeskd; 2013; 157(6):A5563. PubMed ID: 23388140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Big Data and Adverse Drug Reaction Detection.
    Harpaz R; DuMochel W; Shah NH
    Clin Pharmacol Ther; 2016 Mar; 99(3):268-70. PubMed ID: 26575203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knowledge, attitude and practices associated with adverse drug reaction reporting amongst doctors in a teaching hospital.
    Chopra D; Wardhan N; Rehan HS
    Int J Risk Saf Med; 2011; 23(4):227-32. PubMed ID: 22156087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive 4-year survey of adverse drug reactions using a network-based hospital system.
    Chen CJ; Cheng CF; Lin HY; Hung SP; Chen WC; Lin MS
    J Clin Pharm Ther; 2012 Dec; 37(6):647-51. PubMed ID: 22646235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient reporting improves pharmacovigilance.
    Prescrire Int; 2008 Dec; 17(98):241-2. PubMed ID: 19422153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database.
    Shalviri G; Mohammad K; Majdzadeh R; Gholami K
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1136-40. PubMed ID: 17705214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lack of knowledge about the voluntary reporting system of adverse drug reactions as a major cause of underreporting: direct survey among health professionals.
    Pérez García M; Figueras A
    Pharmacoepidemiol Drug Saf; 2011 Dec; 20(12):1295-302. PubMed ID: 21793098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving pharmacovigilance in Europe.
    Moore N; Bégaud B
    BMJ; 2010 Apr; 340():c1694. PubMed ID: 20385717
    [No Abstract]   [Full Text] [Related]  

  • 19. The cost-effectiveness of periodic safety update reports for biologicals in Europe.
    Bouvy JC; Ebbers HC; Schellekens H; Koopmanschap MA
    Clin Pharmacol Ther; 2013 May; 93(5):433-42. PubMed ID: 23549148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Opinion survey of European pharmacovigilance: opinion of French practitioners].
    Pierfitte C; Hanesse B; Royer RJ
    Therapie; 1995; 50(2):171-2. PubMed ID: 7631296
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.